Viewing Study NCT01164475



Ignite Creation Date: 2024-05-05 @ 10:42 PM
Last Modification Date: 2024-10-26 @ 10:22 AM
Study NCT ID: NCT01164475
Status: COMPLETED
Last Update Posted: 2014-02-25
First Post: 2010-07-09

Brief Title: Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkins Lymphoma NHL Weighing Less Than 70 Kilograms
Sponsor: Genzyme a Sanofi Company
Organization: Sanofi

Study Overview

Official Title: A Phase 4 Multicenter Randomized Comparator Trial Evaluating the Standard Weight-Based Dose 024 mgkg Compared to a Fixed Dose 20 mg of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect 5 x 106 CD34 Cellskg in 4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkins Lymphoma Weighing 70 kg
Status: COMPLETED
Status Verified Date: 2014-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkins Lymphoma NHL who received an autologous stem cell transplant
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
MSC12830 OTHER Other Company study code None